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Pulmonary mucormycosis in a patient with chronic obstructive
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Pulmonary mucormycosis is a rare opportunistic infectioncaused by invasive filamentous fungi of the class Zygo-mycetes belonging to the order Mucorales.1 Mucormy-cosis most frequently occurs in diabetic individuals, im-
munosuppressed patients on chronic steroids, patients with
hematologic malignancies, or solid organ or bone marrow trans-
plant recipients. There have been only 2 case reports of pulmonary
mucormycosis in patients with chronic obstructive pulmonary dis-
ease (COPD) who have been treated with oral steroids.2,3
We report a patient with COPD who presented with pulmonary
masses. Diagnosis of the mucormycosis was made by fine needle
aspiration cytology (FNAC).
Clinical Summary
A 72-year-old African-American woman who was a heavy smoker
was admitted with shortness of breath and chest pain. She had a
myocardial infarction (MI) 8 months previously, which was fol-
lowed by a double-vessel coronary artery bypass grafting (CABG)
surgery. The patient developed deep vein thrombosis and bilateral
pulmonary embolism (PE) 2 months after the surgery and was
incidentally found to have a spiculated 2.5-cm left lower lobe lung
mass in spiral computerized tomography (CT) of the chest. How-
ever, further workup of the mass was deferred because of her
acutely worsened condition due to PE. She did not have diabetes
mellitus and denied previous oral steroid treatment except for a
10-day short course of prednisone for presumed COPD exacerba-
tion during her hospitalization 6 months ago.
Physical examination revealed an obese woman with decreased
O2 saturation at 88% on room air. The patient had significant
wheezing in both lung fields. Her legs were swollen with tender-
ness of the left calf. Laboratory analysis including a complete
blood count, chemistry, and cardiac enzymes was remarkable only
for a slightly elevated white blood cell count at 10,700/mm3. Her
international normalized ratio was 1.1 despite coumadin treatment.
The patient was initially worked up for a possible PE. A spiral
CT of the chest did not show any evidence of PE; however, a new
pulmonary mass was detected in the posterior aspect of right upper
lobe in addition to her left-sided lesion (Figure 1). Pulmonary
function tests (PFTs) showed a low forced expiratory volume in 1
second of 0.51 L and a forced vital capacity of 0.93 L. Bronchos-
copy was not performed because the patient was at increased risk
for respiratory failure. Instead, she underwent an FNAC of the
right apical lesion, which showed abundant broad, ribbonlike,
nonseptated fungal elements with right angle branching, consistent
with mucormycosis (Figure 2). However, fungal cultures from
aspiration specimen and sputum samples were negative.
Surgery was deferred because of low PFTs, poor general con-
dition, and bilateral disease. The patient was subsequently started
on amphotericin B lipid complex (Abelcet; Enzon Inc, Bridgewa-
ter, NJ) at a dose of 5 mg/kg. However, she tolerated the drug very
poorly and required dose adjustments, a few days of treatment
interruptions, and finally a switch to liposomal amphotericin B
(Ambisome; Fujisawa Healthcare Inc, Deerfield, Ill) after 2 weeks
because of deteriorating renal function despite aggressive hydra-
tion.
At week 10 of treatment, the patient had a generalized seizure.
A CT scan of the head showed the presence of 2 hypodense masses
in the left frontal and right frontoparietal regions. A CT scan of the
chest showed only minor improvement in the size of the lesions.
The patient refused further diagnostic studies and treatment with
amphotericin B and was discharged from the hospital. The patient
died 4 weeks later.
Discussion
Pulmonary mucormycosis is a rare fungal infection primarily
affecting immunocompromised patients. To our knowledge, 2 pre-
vious cases of mucormycosis in COPD patients associated with
steroid use have been reported.2,3 Moreover, 1 of those reported
patients had diabetes mellitus, which probably was the primary
predisposing factor.2 Our patient is unique in that she did not have
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Figure 1. Computerized tomography of the chest showing cavi-
tated right upper lobe lesion.
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any history of chronic steroid use in the past or any other predis-
posing factors.
Nosocomial mucormycosis may develop in patients who are
hospitalized in intensive care units (ICUs) for prolonged periods
and are relatively immunosuppressed as a result of malnutrition
and medications.1 The emergence of pulmonary masses after MI
and CABG surgery and short-term ICU stay may indicate another
feasible predisposing cause for pulmonary mucormycosis in our
patient.
Histopathologic identification of nonseptated, ribbonlike, irreg-
ular hyphea with right angle branching is essential for diagnosis.
Fungal cultures are frequently negative in more than half of the
cases. FNAC has been reported to be an effective tool to diagnose
pulmonary mucormycosis with characteristic appearance of the
hyphea.4 Our patient is the second case reported in the literature
diagnosed with FNAC of the pulmonary lesion. This report further
illustrates the importance of FNAC in rapid and relatively nonin-
vasive diagnosis of pulmonary mucormycosis.
The outcome of patients with pulmonary mucormycosis is
particularly poor. The prognosis is largely determined by the
underlying predisposing condition and the extent of tissue inva-
sion. The mainstay of treatment is aggressive surgical debridement
combined with antifungal chemotherapy using amphotericin B.5
Treatment of mucormycosis in patients with COPD is further
challenged by the fact that these patients often are not candidates
for definitive surgical resection. Because amphotericin B is the
only effective antifungal agent available, poor tolerability and side
effects make the treatment more difficult. Therefore, early diag-
nosis is crucial to improve treatment outcome with potential cure
by surgical resection where possible.
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Figure 2. Photomicrograph of the fungal elements seen in the fine
needle aspirate of the right posterior lung lesion. Papanicolau
stain; original magnification, 600 under oil immersion.
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